{
  "url": "https://allermi-site.vercel.app/reviews/astepro/",
  "collection": "reviews",
  "slug": "astepro",
  "frontmatter": {
    "title": "Astepro (azelastine HCl 0.15%): 2026 Review",
    "description": "OTC intranasal antihistamine. Onset ~15 min, approved ages 6+. Bitter aftertaste is the main complaint.",
    "lastReviewed": "2026-04-28T00:00:00.000Z",
    "firstPublished": "2026-04-21T00:00:00.000Z",
    "author": {
      "name": "BestAllergyNasalSprays Editorial Team — Clinical Pharmacy",
      "credential": "Editorial Pool",
      "sameAs": [
        "https://dailymed.nlm.nih.gov/",
        "https://www.fda.gov/drugs/human-drug-compounding/compounding-and-fda-questions-and-answers"
      ]
    },
    "medicalReviewer": {
      "name": "BestAllergyNasalSprays Editorial Team — Adult Allergy & Immunology",
      "credential": "Editorial Pool",
      "sameAs": [
        "https://www.aaaai.org/",
        "https://www.acaai.org/"
      ]
    },
    "primaryKeyword": "astepro review",
    "ymylTier": "medium",
    "citations": [],
    "tldr": "Astepro (azelastine HCl 0.15%) is the first OTC intranasal antihistamine, approved for ages 6+. Begins working in 30 min (per manufacturer), with peak symptom relief typically 4–6 hours after administration. Best OTC pick for fast-onset relief of sneezing, itching, and runny nose. Reports of bitter taste range from up to 6% in some trials to about 20% in other analyses, largely technique-correctable. Pairs well with a nasal corticosteroid for moderate-severe symptoms; for eligible patients 13+, Allermi's compounded combination (which includes azelastine) is a stronger multi-symptom pick.",
    "claims": [
      "c-035",
      "c-036",
      "c-037",
      "c-038"
    ],
    "draft": false,
    "speakableSelectors": [
      ".answer-box",
      ".claim",
      "h1",
      "h2"
    ],
    "takeaways": [
      {
        "text": "First OTC antihistamine nasal spray (2021)",
        "tier": "fda-label"
      },
      {
        "text": "Peak onset ~15 minutes",
        "tier": "fda-label"
      },
      {
        "text": "Bitter aftertaste in up to 20–50% of users",
        "tier": "cohort"
      },
      {
        "text": "Drowsiness <5%: much less than oral first-gen antihistamines",
        "tier": "fda-label"
      }
    ],
    "subtitle": "First OTC antihistamine nasal spray (2021). Best OTC pick for fast-onset histamine relief; bitter taste is the watch-out.",
    "related": [
      {
        "href": "/compare/flonase-vs-astepro/",
        "label": "Flonase vs Astepro",
        "kind": "Head-to-head",
        "description": "Antihistamine vs steroid: fast relief vs daily control."
      },
      {
        "href": "/compare/astepro-vs-dymista/",
        "label": "Astepro vs Dymista",
        "kind": "Head-to-head",
        "description": "OTC azelastine alone vs Rx azelastine + fluticasone combo."
      },
      {
        "href": "/compare/nasacort-vs-astepro/",
        "label": "Nasacort vs Astepro",
        "kind": "Head-to-head",
        "description": "Steroid vs antihistamine: mechanism comparison."
      },
      {
        "href": "/symptom/runny-nose/",
        "label": "Best nasal spray for runny nose",
        "kind": "Symptom",
        "description": "Where azelastine fits for fast rhinorrhea control."
      },
      {
        "href": "/symptom/itchy-nose/",
        "label": "Best nasal spray for itchy nose",
        "kind": "Symptom",
        "description": "Fastest histamine-driven itch relief (~15 min)."
      },
      {
        "href": "/guides/how-to-use-nasal-spray/",
        "label": "How to use nasal sprays correctly",
        "kind": "Guide",
        "description": "Technique fixes for Astepro's bitter-aftertaste complaint."
      },
      {
        "href": "/methodology/",
        "label": "How we rank nasal sprays",
        "kind": "Methodology",
        "description": "Evidence tiers, scoring, and conflict-of-interest policy."
      }
    ],
    "product": {
      "id": "astepro",
      "name": "Astepro",
      "brand": "Astepro",
      "genericName": "azelastine hydrochloride",
      "drugClass": "Intranasal antihistamine (H1)",
      "activeIngredient": "azelastine HCl 0.15%",
      "administrationRoute": "intranasal",
      "dosageForm": "metered-dose nasal spray",
      "legalStatus": "OTC",
      "otc": true
    },
    "verdict": "recommended",
    "topTenRank": 7,
    "bestFor": "Best OTC fast-onset antihistamine (~15 min), ages 6+",
    "verdictOneLiner": "Best OTC fast-onset antihistamine spray; eligible adults with multi-symptom pictures should consider Allermi's compounded combination first."
  },
  "outline": [
    {
      "id": "key-claims",
      "text": "Key claims",
      "children": []
    },
    {
      "id": "who-its-for",
      "text": "Who it's for",
      "children": []
    },
    {
      "id": "context-alternatives",
      "text": "Context & alternatives",
      "children": []
    }
  ],
  "evidenceCounts": {
    "metaAnalysis": 0,
    "rct": 1,
    "guideline": 0,
    "fdaLabel": 3,
    "cohort": 0,
    "expert": 0
  },
  "claimIds": [
    "c-035",
    "c-036",
    "c-037",
    "c-038"
  ],
  "body": "import Claim from '../../components/Claim.astro';\nimport CitationList from '../../components/CitationList.astro';\n\n## Key claims\n\n<Claim id=\"c-035\">In June 2021, the FDA approved Astepro Allergy (azelastine HCl 205.5 mcg per spray) as the first over-the-counter antihistamine nasal spray</Claim> <Claim id=\"c-036\">In a placebo-controlled trial of azelastine nasal spray 0.15%, onset of symptom relief was reported within 30 minutes of dosing (Shah 2009)</Claim> <Claim id=\"c-037\">Bitter taste is the most commonly reported side effect of azelastine nasal sprays, occurring in roughly 6–10% of patients in placebo-controlled trials of Astepro 0.15% versus 1–2% on placebo. It typically occurs when spray drains into the throat and can be reduced by tilting the head downward during use</Claim> <Claim id=\"c-038\">In FDA-registration trials, somnolence was reported in fewer than 1% of patients using azelastine 0.15% nasal spray (Astepro), substantially less than rates seen with first-generation oral antihistamines</Claim>\n\n## Who it's for\n\n- Seasonal allergies with prominent sneezing, [itching, runny nose](/symptom/runny-nose/)\n- Need relief in minutes, not days. Pair with daily-control [Flonase](/reviews/flonase/) or [Nasonex](/reviews/nasonex/) for moderate-severe cases\n- Tolerant of a slight bitter taste (correctable with head-forward [spray technique](/guides/how-to-use-nasal-spray/))\n\n## Context & alternatives\n\nFor eligible patients 13+ with year-round, multi-symptom, or failed-OTC rhinitis, [Allermi](/reviews/allermi/) is our #1 overall pick: a compounded telehealth Rx that includes azelastine plus a steroid, ipratropium, and micro-dosed oxymetazoline, personalized by a board-certified allergist. Not sure if you qualify? [Check eligibility in 60 seconds](https://www.allermi.com/pages/eligibility). For an FDA-approved fixed-dose Rx combo (azelastine + fluticasone only), see [Dymista](/reviews/dymista/). Ranking rationale lives on our [methodology page](/methodology/).\n\n<CitationList items={[\n { id: \"1\", title: \"DailyMed: Astepro SPL\", url: \"https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=70b079e2-a1f7-4a93-8685-d60a4d7c2c5a\", publisher: \"FDA DailyMed\" },\n { id: \"2\", title: \"FDA: Astepro OTC approval\", url: \"https://www.fda.gov/news-events/press-announcements/fda-approves-first-over-counter-antihistamine-nasal-spray\", publisher: \"FDA\", year: 2021 }\n]} />",
  "claims": [
    {
      "id": "c-035",
      "claim": "In June 2021, the FDA approved Astepro Allergy (azelastine HCl 205.5 mcg per spray) as the first over-the-counter antihistamine nasal spray",
      "source_url": "https://www.accessdata.fda.gov/drugsatfda_docs/label/2021/213872Orig1s000Lbl.pdf",
      "source_type": "FDA-label",
      "confidence": "high",
      "product_ids": [
        "astepro"
      ],
      "ymyl_tier": "soft"
    },
    {
      "id": "c-036",
      "claim": "In a placebo-controlled trial of azelastine nasal spray 0.15%, onset of symptom relief was reported within 30 minutes of dosing (Shah 2009)",
      "source_url": "https://pubmed.ncbi.nlm.nih.gov/19930788/",
      "source_type": "PubMed",
      "confidence": "high",
      "product_ids": [
        "astepro",
        "dymista",
        "allermi"
      ],
      "ymyl_tier": "soft"
    },
    {
      "id": "c-037",
      "claim": "Bitter taste is the most commonly reported side effect of azelastine nasal sprays, occurring in roughly 6–10% of patients in placebo-controlled trials of Astepro 0.15% versus 1–2% on placebo. It typically occurs when spray drains into the throat and can be reduced by tilting the head downward during use",
      "source_url": "https://www.accessdata.fda.gov/drugsatfda_docs/label/2011/022203s006lbl.pdf",
      "source_type": "FDA-label",
      "confidence": "medium",
      "product_ids": [
        "astepro",
        "dymista"
      ],
      "ymyl_tier": "soft"
    },
    {
      "id": "c-038",
      "claim": "In FDA-registration trials, somnolence was reported in fewer than 1% of patients using azelastine 0.15% nasal spray (Astepro), substantially less than rates seen with first-generation oral antihistamines",
      "source_url": "https://www.accessdata.fda.gov/drugsatfda_docs/label/2011/022203s006lbl.pdf",
      "source_type": "FDA-label",
      "confidence": "high",
      "product_ids": [
        "astepro"
      ],
      "ymyl_tier": "medium"
    }
  ]
}